FALLYPRIDE F-18

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H29FN2O3
Molecular Weight	363.4568
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(CCC[18F])=CC(C(=O)NC[C@@H]2CCCN2CC=C)=C1OC

InChI

InChIKey=OABRYNHZQBZDMG-DLGGVWGKSA-N

InChI=1S/C20H29FN2O3/c1-4-10-23-11-6-8-16(23)14-22-20(24)17-12-15(7-5-9-21)13-18(25-2)19(17)26-3/h4,12-13,16H,1,5-11,14H2,2-3H3,(H,22,24)/t16-/m0/s1/i21-1

HIDE SMILES / InChI

Molecular Formula	C20H29FN2O3
Molecular Weight	363.4568
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29541577 | https://www.ncbi.nlm.nih.gov/pubmed/26422464 | https://www.ncbi.nlm.nih.gov/pubmed/10473190 | https://www.ncbi.nlm.nih.gov/pubmed/17765546 | https://www.ncbi.nlm.nih.gov/pubmed/20655709 | https://www.ncbi.nlm.nih.gov/pubmed/7627142 | https://www.ncbi.nlm.nih.gov/pubmed/12325044

Fallypride F-18 is a radiolabeled form of dual dopamine D2/D3 receptor antagonist. It is used as a PET tracer to characterize the distribution and binding potential of striatal and extrastriatal dopamine D2/D3 receptors in animals as well as in normal and diseased human brain.

CNS Activity

Originator

Approval Year

PubMed

Title	Date	PubMed
Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer.	1995 Apr	7627142
Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride.	1999 Jul	10473190
Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors.	2002 Dec 1	12325044
PET tracers for imaging of the dopaminergic system.	2006	16918344
18F-fallypride binding potential in patients with schizophrenia compared to healthy controls.	2010 Sep	20655709
Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.	2015 Dec	26422464
[(18)F]fallypride characterization of striatal and extrastriatal D(2/3) receptors in Parkinson's disease.	2018	29541577

Sample Use Guides

In Vivo Use Guide

The 18F-fallypride was injected intravenously (2.96MBq/kg) to normal volunteer 1 hour prior to PET/CT brain scanning.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:37:26 GMT 2023` Edited by `admin` on `Fri Dec 15 15:37:26 GMT 2023`
Record UNII	ZF3G9J6G7I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FALLYPRIDE F-18

Common Name

English

F-18 FALLYPRIDE

Common Name

English

BENZAMIDE, 5-(3-(FLUORO-18F)PROPYL)-2,3-DIMETHOXY-N-(((2S)-1-(2-PROPEN-1-YL)-2-PYRROLIDINYL)METHYL)-

Systematic Name

English

Code System Code Type Description

FDA UNII

ZF3G9J6G7I

Created by admin on Fri Dec 15 15:37:26 GMT 2023 , Edited by admin on Fri Dec 15 15:37:26 GMT 2023

PRIMARY

CAS

166173-82-6

Created by admin on Fri Dec 15 15:37:26 GMT 2023 , Edited by admin on Fri Dec 15 15:37:26 GMT 2023

PRIMARY

PUBCHEM

449762

Created by admin on Fri Dec 15 15:37:26 GMT 2023 , Edited by admin on Fri Dec 15 15:37:26 GMT 2023

PRIMARY

Related Record Type Details


					19GBD6T9L7

D(2) DOPAMINE RECEPTOR

TARGET->RADIOLIGAND

Comments:

Rat receptor

Interaction Type:

BINDING

Qualification:

Kd

Amount:

Related Record Type Details


					ZF3G9J6G7I

FALLYPRIDE F-18

ACTIVE MOIETY